Soma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Soma has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Andrei R. Shustov
University of Washington Medical Center
1 shared publication- Andrei Shustov
Division of Hematology, Department of Medicine, University of Washington, Seattle, USA
1 shared publication Cheng Ding
Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, 98109
1 shared publicationClaire Murphy
University of Washington Medical Center
1 shared publicationEmily Glynn
University of Washington Medical Center
1 shared publication- Gordon Starkebaum
University of Washington, Division of Rheumatology, 1959 NE Pacific St., Box 356428, Seattle, WA, 98195-6428, USA
1 shared publication
Latest Publications
- Open Access
- 6 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15482
Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome
Sézary syndrome (SS) is a form of cutaneous T-cell lymphoma (CTCL), demonstrating leukemic involvement of malignant T-cells. Known systemic sequelae of SS include hemophagocytic syndrome-induced anemia, normocytic anemia secondary to bone marrow infiltration, and pancytopenia. We report a patient with SS, initially demonstrating widespread morbilliform eruption, who presented with malignancy-related microangiopathic hemolytic anemia (MAHA). Our findings represent a novel presentation of SS that will inform the differential diagnosis and treatment of future SS patients presenting with anemia and thrombocytopenia.
- 6 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15482
Open AccessFatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome
Sézary syndrome (SS) is a form of cutaneous T-cell lymphoma (CTCL), demonstrating leukemic involvement of malignant T-cells. Known systemic sequelae of SS include hemophagocytic syndrome-induced anemia, normocytic anemia secondary to bone marrow infiltration, and pancytopenia. We report a patient with SS, initially demonstrating widespread morbilliform eruption, who presented with malignancy-related microangiopathic hemolytic anemia (MAHA). Our findings represent a novel presentation of SS that will inform the differential diagnosis and treatment of future SS patients presenting with anemia and thrombocytopenia.
- 7 December 2018
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (2) , 603-608
Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoimmune disorders, malignancies, and medications. We describe a case of a patient with axial spondyloarthritis (axSpA) treated with adalimumab, who presented with MAS.
- 7 December 2018
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (2) , 603-608
Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoimmune disorders, malignancies, and medications. We describe a case of a patient with axial spondyloarthritis (axSpA) treated with adalimumab, who presented with MAS.
- 2 March 2018
- Published by Springer Nature in Journal of Hematopathology
- Vol. 11 (2) , 45-49
Leukemic phase of primary cutaneous anaplastic large-cell lymphoma (ALK-negative), with downregulation of CD30
- 2 March 2018
- Published by Springer Nature in Journal of Hematopathology
- Vol. 11 (2) , 45-49
Leukemic phase of primary cutaneous anaplastic large-cell lymphoma (ALK-negative), with downregulation of CD30
- Open Access
- 7 December 2016
- Published by Association of American Medical Colleges in MedEdPORTAL
- Vol. 12 (12) , 10513
Interactive Tutorial of Normal Lymph Node Histology for Pathology and Laboratory Medicine Residents and Medical Students
Computer-based e-learning modules have been shown to be an effective learning tool in medical education. However, readily available, interactive, computer-based modules specifically educating on the histology of the normal lymph node have not been developed. Using Microsoft PowerPoint, I developed a macro-enabled slide show illustrating and describing the architectural, cytomorphologic, and immunophenotypic features of the normal lymph node. This resource can be made available to medical students and residents prior to their hematopathology service rotation, as well as during their rotation should they want to review the module. The tutorial is interactive, with mixed-media features, links to pre- and postquizzes, and an interactive quiz at the end to solidify understanding and address areas of confusion. After 1 year of elective implementation, eight out of 13 students chose to use the tutorial, four of whom gave formal feedback in the form of a survey and three verbal feedback. All feedback was positive, finding the tutorial a useful adjunct. Although extensive implementation was limited given the small numbers that rotate through the hematopathology service on a yearly basis, an interactive, computer-based module was found helpful by the students in learning normal lymph node histology. This 1-year experience demonstrated that the normal lymph node tutorial can be used as an effective adjunct in educating pathology residents and medical students on normal lymph node cytomorphology and immunoarchitecture in the context of a busy clinical patient care setting. Continued learner feedback will be necessary to further enhance the quality of this platform for education.
- 7 December 2016
- Published by Association of American Medical Colleges in MedEdPORTAL
- Vol. 12 (12) , 10513
Open AccessInteractive Tutorial of Normal Lymph Node Histology for Pathology and Laboratory Medicine Residents and Medical Students
Computer-based e-learning modules have been shown to be an effective learning tool in medical education. However, readily available, interactive, computer-based modules specifically educating on the histology of the normal lymph node have not been developed. Using Microsoft PowerPoint, I developed a macro-enabled slide show illustrating and describing the architectural, cytomorphologic, and immunophenotypic features of the normal lymph node. This resource can be made available to medical students and residents prior to their hematopathology service rotation, as well as during their rotation should they want to review the module. The tutorial is interactive, with mixed-media features, links to pre- and postquizzes, and an interactive quiz at the end to solidify understanding and address areas of confusion. After 1 year of elective implementation, eight out of 13 students chose to use the tutorial, four of whom gave formal feedback in the form of a survey and three verbal feedback. All feedback was positive, finding the tutorial a useful adjunct. Although extensive implementation was limited given the small numbers that rotate through the hematopathology service on a yearly basis, an interactive, computer-based module was found helpful by the students in learning normal lymph node histology. This 1-year experience demonstrated that the normal lymph node tutorial can be used as an effective adjunct in educating pathology residents and medical students on normal lymph node cytomorphology and immunoarchitecture in the context of a busy clinical patient care setting. Continued learner feedback will be necessary to further enhance the quality of this platform for education.
- Open Access
- 21 January 2016
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 90 (5) , 440-448
Small, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: Does this finding indicate an accelerated course?
Background The 2008 WHO is not specific regarding subclassification of chronic myelogenous leukemia (CML) with less than 20% abnormal B lymphoid blasts (ABLB), and suggests patients with ABLB often show rapid progression (Swerdlow, 2008). Recent studies have shown variable outcomes when small abnormal B cell populations are seen by flow cytometry (El Rassi et al., Cancer 2015; 121:872–875; Vrotsos et al., Cytometry B Clin Cytom 2015). Methods The hematopathology database was searched (7.4-year period), and patients identified through routine clinical study, who were BCR-ABL1 positive CML and had an ABLB of less than 20%. Flow cytometric (FC) and histologic data was evaluated to determine immunophenotypic abnormalities, immunohistochemical patterns, and percentage of ABLB, hematogones, and mature B cells. Results Seven patients with CML and ABLB identified by FC studies were found, five of which also had available histologic material to review. ABLB by FC ranged from 0.006% to 3.4%, typically demonstrated an immunophenotype with increased CD10, increased CD19, and decreased CD38, without myeloid antigens, abnormalities similar to that reported previously (Vrotsos et al., Cytometry B Clin Cytom 2015). The ABLB population was found only in diagnostic samples and always with more numerous hematogones. By immunohistochemistry, three of five patients showed ≥10% TdT positive cells. All patients showed a response to tyrosine kinase inhibitor therapy, and no patients progressed to clinical lymphoid blast phase. Conclusions Immature B cells, occasionally including a small subset with an abnormal phenotype can be observed in chronic phase CML at diagnosis. We believe an approach incorporating clinical data, cytogenetic/molecular findings, and morphologic evaluation may be helpful when determining the best management of CML patients at diagnosis if small ABLB populations are identified by FC. © 2016 Clinical Cytometry Society
- 21 January 2016
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 90 (5) , 440-448
Open AccessSmall, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: Does this finding indicate an accelerated course?
Background The 2008 WHO is not specific regarding subclassification of chronic myelogenous leukemia (CML) with less than 20% abnormal B lymphoid blasts (ABLB), and suggests patients with ABLB often show rapid progression (Swerdlow, 2008). Recent studies have shown variable outcomes when small abnormal B cell populations are seen by flow cytometry (El Rassi et al., Cancer 2015; 121:872–875; Vrotsos et al., Cytometry B Clin Cytom 2015). Methods The hematopathology database was searched (7.4-year period), and patients identified through routine clinical study, who were BCR-ABL1 positive CML and had an ABLB of less than 20%. Flow cytometric (FC) and histologic data was evaluated to determine immunophenotypic abnormalities, immunohistochemical patterns, and percentage of ABLB, hematogones, and mature B cells. Results Seven patients with CML and ABLB identified by FC studies were found, five of which also had available histologic material to review. ABLB by FC ranged from 0.006% to 3.4%, typically demonstrated an immunophenotype with increased CD10, increased CD19, and decreased CD38, without myeloid antigens, abnormalities similar to that reported previously (Vrotsos et al., Cytometry B Clin Cytom 2015). The ABLB population was found only in diagnostic samples and always with more numerous hematogones. By immunohistochemistry, three of five patients showed ≥10% TdT positive cells. All patients showed a response to tyrosine kinase inhibitor therapy, and no patients progressed to clinical lymphoid blast phase. Conclusions Immature B cells, occasionally including a small subset with an abnormal phenotype can be observed in chronic phase CML at diagnosis. We believe an approach incorporating clinical data, cytogenetic/molecular findings, and morphologic evaluation may be helpful when determining the best management of CML patients at diagnosis if small ABLB populations are identified by FC. © 2016 Clinical Cytometry Society